Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) Equity Ratio (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Equity Ratio for 5 consecutive years, with 1.1 as the latest value for Q1 2026.

  • For Q1 2026, Equity Ratio rose 3.98% year-over-year to 1.1; the TTM value through Mar 2026 reached 1.1, up 3.98%, while the annual FY2025 figure was 1.69, 152.25% down from the prior year.
  • Equity Ratio hit 1.1 in Q1 2026 for Phathom Pharmaceuticals, up from 1.69 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.26 in Q1 2022 and bottomed at 1.76 in Q3 2025.
  • Average Equity Ratio over 5 years is 0.64, with a median of 0.48 recorded in 2024.
  • Year-over-year, Equity Ratio skyrocketed 302.54% in 2023 and then crashed 1202.54% in 2024.
  • Phathom Pharmaceuticals' Equity Ratio stood at 0.45 in 2022, then soared by 61.27% to 0.18 in 2023, then plummeted by 281.25% to 0.67 in 2024, then tumbled by 152.25% to 1.69 in 2025, then skyrocketed by 34.69% to 1.1 in 2026.
  • According to Business Quant data, Equity Ratio over the past three periods came in at 1.1, 1.69, and 1.76 for Q1 2026, Q4 2025, and Q3 2025 respectively.